Initial Statement of Beneficial Ownership (3)
06 Maggio 2022 - 6:25PM
Edgar (US Regulatory)
FORM 3
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0104
Estimated average burden
hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
|
1. Name and Address of Reporting Person
*
Dahowski Diane |
2. Date of Event Requiring Statement (MM/DD/YYYY)
4/27/2022
|
3. Issuer Name and Ticker or Trading Symbol
BIO-RAD LABORATORIES, INC. [BIO BIOB]
|
|
(Last)
(First)
(Middle)
C/O BIO-RAD LABORATORIES, INC., 1000 ALFRED NOBEL DRIVE |
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)
_____ Director _____ 10% Owner
___X___ Officer (give title below) _____ Other (specify below)
EVP, Global Supply Chain / |
|
(Street)
HERCULES, CA 94547
(City)
(State)
(Zip)
| 5. If Amendment, Date Original Filed(MM/DD/YYYY)
| 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Beneficially Owned
|
1.Title of Security
(Instr. 4) | 2. Amount of Securities Beneficially Owned
(Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5) | 4. Nature of Indirect Beneficial Ownership
(Instr. 5) |
| Bio-Rad A Common Stock | 9007.9640 | D | |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security
(Instr. 4) | 2. Date Exercisable and Expiration Date
(MM/DD/YYYY) | 3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5) | 6. Nature of Indirect Beneficial Ownership
(Instr. 5) |
| Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
| Restricted Stock Units | (1) | (1) | Bio-Rad A Common Stock | 600 | $0 (6) | D | |
| Restricted Stock Units | (2) | (2) | Bio-Rad A Common Stock | 1200 | $0 (6) | D | |
| Restricted Stock Units | (3) | (3) | Bio-Rad A Common Stock | 1485 | $0 (6) | D | |
| Restricted Stock Units | (4) | (4) | Bio-Rad A Common Stock | 1083 | $0 (6) | D | |
| Restricted Stock Units | (5) | (5) | Bio-Rad A Common Stock | 1317 | $0 (6) | D | |
| Non-Qualified Stock Option (right to buy) | (7) | 9/2/2030 | Bio-Rad A Common Stock | 1444 | $524.30 | D | |
| Non-Qualified Stock Option (right to buy) | (8) | 9/1/2031 | Bio-Rad A Common Stock | 1317 | $814.95 | D | |
| Explanation of Responses: |
| (1) | On September 5, 2017, the reporting person was granted 3,000 restricted stock units, vesting in five equal annual installments beginning on the first anniversary of the grant date. |
| (2) | On September 4, 2018, the reporting person was granted 3,000 restricted stock units, vesting in five equal annual installments beginning on the first anniversary of the grant date. |
| (3) | On September 3, 2019, the reporting person was granted 2,475 restricted stock units, vesting in five equal annual installments beginning on the first anniversary of the grant date. |
| (4) | On September 2, 2020, the reporting person was granted 1,444 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. |
| (5) | On September 1, 2021, the reporting person was granted 1,317 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. |
| (6) | Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. |
| (7) | The option, representing a right to purchase a total of 1,444 shares, becomes exercisable in four equal annual installments beginning on September 2, 2021, which is the first anniversary of the date on which the option was granted. |
| (8) | The option, representing a right to purchase a total of 1,317 shares, becomes exercisable in four equal annual installments beginning on September 1, 2022, which is the first anniversary of the date on which the option was granted. |
Reporting Owners
|
| Reporting Owner Name / Address | Relationships |
| Director | 10% Owner | Officer | Other |
Dahowski Diane
C/O BIO-RAD LABORATORIES, INC.
1000 ALFRED NOBEL DRIVE
HERCULES, CA 94547 |
|
| EVP, Global Supply Chain |
|
Signatures
|
| /s/ Diane Dahowski | | 5/6/2022 |
| **Signature of Reporting Person | Date |
| Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. |
| * | If the form is filed by more than one reporting person, see Instruction 5(b)(v). |
| ** | Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). |
| Note: | File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. |
| Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. |
Grafico Azioni Bio Rad Laboratories (NYSE:BIO.B)
Storico
Da Apr 2024 a Mag 2024
Grafico Azioni Bio Rad Laboratories (NYSE:BIO.B)
Storico
Da Mag 2023 a Mag 2024
